Cytori said it is working with the Food and Drug Administration and the study's safety monitoring board to understand how the problems occurred. The study hold means the company will not complete enrollment of its lead study for the treatment by the end of 2014, as previously stated.
Cytori makes equipment that separates adult stem cells from fat tissue using a combination of spinning motions and chemical reactions. Company researchers are studying the use of these purified stem cells in treating a variety of medical conditions, including heart disease.
Cytori's procedure involves harvesting stem cells from fat removed during liposuction procedures and injecting the cells into the heart.